Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Combo PharmaASX:S66 20 Earnings Yield (Joel Greenblatt) % is 16.52% as of Jun. 2026. GuruFocus rates ASX:S66 with a GF Score™ of 20/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 4 warning signs investors should review. Among 2,043 Consumer Packaged Goods companies, Star Combo Pharma ranks better than 83.9% on this metric.
Star Combo Pharma's Enterprise Value for the quarter that ended in Jun. 2026 was A$4.42 Mil.
Star Combo Pharma's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was A$0.73 Mil. Star Combo Pharma's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 16.52%.
The historical rank and industry rank for Star Combo Pharma's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ASX:S66'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -149.19 Med: -6.26 Max: 636.32
Current: 14.35
During the past 10 years, the highest Earnings Yield (Joel Greenblatt) of Star Combo Pharma was 636.32%. The lowest was -149.19%. And the median was -6.26%.
ASX:S66's Earnings Yield (Joel Greenblatt) % is ranked better than 83.9% of 2043
companies
in the Consumer Packaged Goods industry
Industry Median: 5.99
vs ASX:S66: 14.35
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Star Combo Pharma's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Star Combo Pharma (ASX:S66) Earnings Yield (Joel Greenblatt) % Explanation
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Star Combo Pharma Earnings Yield (Joel Greenblatt) % Related Terms
Star Combo Pharma Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Star Combo Pharma's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Combo Pharma Earnings Yield (Joel Greenblatt) % Chart
For the Household & Personal Products subindustry, Star Combo Pharma's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma Earnings Yield (Joel Greenblatt) % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's Earnings Yield (Joel Greenblatt) % falls into.
Star Combo Pharma Earnings Yield (Joel Greenblatt) % Calculation
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Star Combo Pharmas Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Jun. 2026 is calculated as
For company reported semi-annually or annually, GuruFocus only calculate annual data for Earnings Yield (Joel Greenblatt) and apply the annual figure to corresponding quarter.
What does a Earnings Yield (Joel Greenblatt) % of 16.52% mean?
Star Combo Pharma (ASX:S66) has a Earnings Yield (Joel Greenblatt) % of 16.52% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Star Combo Pharma and its competitors. According to the industry distribution chart, Star Combo Pharma ranks #329 out of 2043 companies in the Consumer Packaged Goods industry, placing it in the top 16.1%.
Is Star Combo Pharma's Earnings Yield (Joel Greenblatt) % too high?
Star Combo Pharma's current Earnings Yield (Joel Greenblatt) % is 16.52%. The Consumer Packaged Goods industry median Earnings Yield (Joel Greenblatt) % is 5.99. Star Combo Pharma's value of 16.52% is 175.8% above this industry median. Based on the distribution chart, Star Combo Pharma ranks #329 out of 2043 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Star Combo Pharma has a GF Score™ of 20/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's Earnings Yield (Joel Greenblatt) % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Star Combo Pharma ranks #329 out of 2043 companies for Earnings Yield (Joel Greenblatt) %. This places Star Combo Pharma in the top 16% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 5.99. Star Combo Pharma's value of 16.52% is 175.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Consumer Packaged Goods company?
The median Earnings Yield (Joel Greenblatt) % among Consumer Packaged Goods companies is 5.99, based on 2,043 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Combo Pharma's current Earnings Yield (Joel Greenblatt) % of 16.52% is 175.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Star Combo Pharma and its competitors. For the Consumer Packaged Goods industry, the median Earnings Yield (Joel Greenblatt) % is 5.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Combo Pharma's current Earnings Yield (Joel Greenblatt) % is 16.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.14 — trading 7.7% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 16.52% and 175.8% above the Consumer Packaged Goods industry median of 5.99. Star Combo Pharma's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current Earnings Yield (Joel Greenblatt) % is 16.52% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be overvalued.
The current stock price of A$0.14 is trading 7.7% above its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
Earnings Yield (Joel Greenblatt) %: 16.52%
GF Value™: A$0.13 vs. price of A$0.14 (7.7% above fair value)
Industry Position: 175.8% above the Consumer Packaged Goods median (#329 of 2043)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
20GF Score
Get the complete analysis for ASX:S66
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
